CA2628241C
(en)
|
2005-11-07 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
KR20150116465A
(ko)
|
2007-02-15 |
2015-10-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진물질
|
CA2702289A1
(en)
*
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
EP2952202B1
(de)
*
|
2008-06-17 |
2017-10-18 |
Indiana University Research and Technology Corporation |
Gip-basierte gemischte agonisten zur behandlung von stoffwechselkrankheiten und fettleibigkeit
|
NZ589847A
(en)
|
2008-06-17 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Glucagon/glp-1 receptor co-agonists
|
MA32970B1
(fr)
|
2008-12-15 |
2012-01-02 |
Zealand Pharma As |
Analogues du glucagon
|
JP5635531B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
CN102292347A
(zh)
*
|
2008-12-15 |
2011-12-21 |
西兰制药公司 |
胰高血糖素类似物
|
WO2010070255A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
AR074811A1
(es)
|
2008-12-19 |
2011-02-16 |
Univ Indiana Res & Tech Corp |
Profarmaco de peptido de la superfamilia de glucagon basados en amida
|
KR20120087875A
(ko)
|
2009-06-16 |
2012-08-07 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Gip 수용체-활성 글루카곤 화합물
|
ME02220B
(me)
|
2009-07-13 |
2016-02-20 |
Zealand Pharma As |
Analozi acilovanog glukagona
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
EP2525809B1
(de)
|
2010-01-20 |
2016-08-03 |
Zealand Pharma A/S |
Glukagon-glp1 doppelagonisten zur behandlung von herzkrankheiten
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US20130143798A1
(en)
|
2010-03-26 |
2013-06-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
US20130053310A1
(en)
|
2010-03-26 |
2013-02-28 |
Novo Nordisk A/S |
Novel glucagon analogues
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
CN107129538B
(zh)
|
2010-04-27 |
2021-07-16 |
西兰制药公司 |
Glp-1受体激动剂和胃泌素的肽缀合物及其用途
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
UY33462A
(es)
*
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
BR112012033225A2
(pt)
*
|
2010-06-24 |
2017-06-20 |
Zealand Pharma As |
análogos do glucagon
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
KR101382593B1
(ko)
|
2010-07-21 |
2014-04-10 |
한미사이언스 주식회사 |
신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
|
BR112013015389A2
(pt)
|
2010-12-22 |
2016-11-22 |
Univ Indiana Res & Tech Corp |
análogo de glucagon exibindo atividade de receptor gip
|
MA34913B1
(fr)
|
2011-01-20 |
2014-02-01 |
Zealand Pharma As |
Combinaison d'analogues du glucagon acylé à des analogues d'insuline
|
WO2012121746A2
(en)
*
|
2011-03-09 |
2012-09-13 |
The General Hospital Corporation |
Imaging beta cell mass
|
CN103596583B
(zh)
|
2011-03-28 |
2016-07-27 |
诺沃—诺迪斯克有限公司 |
新型胰高血糖素类似物
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
WO2012153196A2
(en)
|
2011-05-10 |
2012-11-15 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
RU2014101697A
(ru)
|
2011-06-22 |
2015-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты рецепторов глюкагона/glp-1
|
CN103857408B
(zh)
|
2011-06-22 |
2017-04-12 |
印第安那大学科技研究公司 |
胰高血糖素/glp‑1受体协同激动剂
|
EP2729493B1
(de)
|
2011-07-04 |
2020-06-10 |
IP2IPO Innovations Limited |
Neue verbindungen und ihre auswirkungen auf das ernährungsverhalten
|
EP2567959B1
(de)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
CA2849673A1
(en)
|
2011-09-23 |
2013-03-28 |
Novo Nordisk A/S |
Novel glucagon analogues
|
EP2760862B1
(de)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
|
WO2013064669A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
BR112014015681A2
(pt)
|
2011-12-23 |
2019-09-24 |
Boehringer Ingelheim Int |
análogos de glucagon
|
WO2013098408A1
(en)
|
2011-12-30 |
2013-07-04 |
Zealand Pharma A/S |
Glucagon and cck receptor agonist peptide conjugates
|
US10100097B2
(en)
|
2012-05-03 |
2018-10-16 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
CN104583234A
(zh)
|
2012-06-14 |
2015-04-29 |
赛诺菲 |
毒蜥外泌肽-4肽类似物
|
CN104662038B
(zh)
|
2012-07-23 |
2018-11-06 |
西兰制药公司 |
胰高血糖素类似物
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
CN105142621A
(zh)
|
2012-10-24 |
2015-12-09 |
国家健康科学研究所 |
用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
|
BR112015014510A2
(pt)
|
2012-12-21 |
2017-11-21 |
Sanofi Sa |
agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
|
US20160024169A1
(en)
|
2013-03-14 |
2016-01-28 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
MX365465B
(es)
|
2013-03-21 |
2019-06-04 |
Sanofi Aventis Deutschland |
Sintesis de productos peptidicos que contienen imida ciclica.
|
SG11201506804VA
(en)
|
2013-03-21 |
2015-09-29 |
Sanofi Aventis Deutschland |
Synthesis of hydantoin containing peptide products
|
AR095986A1
(es)
|
2013-04-03 |
2015-11-25 |
Sanofi Sa |
Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
|
KR20160021758A
(ko)
|
2013-04-18 |
2016-02-26 |
노보 노르디스크 에이/에스 |
의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
CN105745222A
(zh)
|
2013-10-17 |
2016-07-06 |
西兰制药公司 |
酰化胰高血糖素类似物
|
CA2929107C
(en)
|
2013-11-06 |
2023-09-26 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
TWI670281B
(zh)
|
2013-11-06 |
2019-09-01 |
西蘭製藥公司 |
Gip-glp-1雙重促效劑化合物及方法
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
|
WO2015086731A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
EP3080149A1
(de)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Duale glp-1-/glucagon-rezeptoragonisten
|
MX2016010599A
(es)
|
2014-02-18 |
2016-11-18 |
Novo Nordisk As |
Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
WO2016049190A1
(en)
|
2014-09-24 |
2016-03-31 |
Indiana University Research And Technology Corporation |
Incretin-insulin conjugates
|
ES2883345T3
(es)
|
2014-10-29 |
2021-12-07 |
Zealand Pharma As |
Compuestos agonistas del GIP y métodos
|
PE20171154A1
(es)
|
2014-12-30 |
2017-08-16 |
Hanmi Pharm Ind Co Ltd |
Derivados de glucagon con estabilidad mejorada
|
MY175669A
(en)
|
2015-02-17 |
2020-07-03 |
Lilly Co Eli |
Nasal powder formulation for treatment of hypoglycemia
|
MX2017011182A
(es)
|
2015-03-18 |
2018-06-06 |
Zealand Pharma As |
Analogos de amilina.
|
ES2805743T3
(es)
|
2015-03-24 |
2021-02-15 |
Inst Nat Sante Rech Med |
Método y composición farmacéutica para uso en el tratamiento de la diabetes
|
WO2016168388A2
(en)
|
2015-04-14 |
2016-10-20 |
Palatin Technologies, Inc. |
Therapies for obesity, diabetes and related indications
|
JP6989385B2
(ja)
|
2015-04-16 |
2022-01-05 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|
WO2016198628A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
|
MX2017016845A
(es)
|
2015-06-30 |
2018-08-01 |
Hanmi Pharm Ind Co Ltd |
Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
CN108699125B
(zh)
|
2015-12-31 |
2022-10-28 |
韩美药品株式会社 |
胰高血糖素/glp-1/gip受体三重激动剂
|
CN109562144A
(zh)
*
|
2016-06-09 |
2019-04-02 |
阿米德生物有限责任公司 |
胰高血糖素类似物及其使用方法
|
UA126662C2
(uk)
*
|
2016-06-29 |
2023-01-11 |
Ханмі Фарм. Ко., Лтд. |
Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування
|
LT3494120T
(lt)
|
2016-08-05 |
2021-05-25 |
Boehringer Ingelheim International Gmbh |
Oksadiazolopiridino dariniai, skirti naudoti kaip grelino o-aciltransferazės (goat) inhibitoriai
|
US10071140B2
(en)
|
2016-09-09 |
2018-09-11 |
Zealand Pharma A/S |
Amylin analogues
|
TW201832783A
(zh)
|
2016-12-02 |
2018-09-16 |
法商賽諾菲公司 |
包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物
|
BR112019010624A2
(pt)
|
2016-12-09 |
2019-10-22 |
Zealand Pharma As |
agonistas duplos de glp-1/glp-2 acilados e composição
|
SG11202006300XA
(en)
|
2018-02-02 |
2020-07-29 |
Boehringer Ingelheim Int |
Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
|
JP7083397B2
(ja)
|
2018-02-02 |
2022-06-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グレリンo-アシルトランスフェラーゼ(goat)阻害剤として使用するためのトリアゾロピリミジン誘導体
|
KR20200116978A
(ko)
|
2018-02-02 |
2020-10-13 |
베링거 인겔하임 인터내셔날 게엠베하 |
그렐린 o-아실 트랜스퍼라제(goat) 억제제로서의 벤질-치환된, (피리딘-3-일)메틸-치환된 또는 (피리딘-4-일)메틸-치환된 옥사디아졸로피리딘 유도체
|
EP3746449B1
(de)
|
2018-02-02 |
2022-03-30 |
Boehringer Ingelheim International GmbH |
Pyrazol- und indazol-substituierte oxadiazolopyridinderivate zur verwendung als inhibitoren der ghrelin-o-acyltransferase (goat)
|
CN112996811B
(zh)
|
2018-12-21 |
2022-11-22 |
江苏恒瑞医药股份有限公司 |
双特异性蛋白
|
TWI771669B
(zh)
|
2019-04-26 |
2022-07-21 |
美商美國禮來大藥廠 |
製備穩定胜肽調配物之方法
|
CN114641303A
(zh)
|
2019-11-11 |
2022-06-17 |
勃林格殷格翰国际有限公司 |
Npy2受体激动剂
|
JP2023526353A
(ja)
|
2020-05-22 |
2023-06-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの連続製造方法
|
JP2023526351A
(ja)
|
2020-05-22 |
2023-06-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの製造方法
|
EP4192853A1
(de)
|
2020-08-07 |
2023-06-14 |
Boehringer Ingelheim International GmbH |
Lösliche npy2-rezeptoragonisten
|
JP2024516395A
(ja)
|
2021-04-27 |
2024-04-15 |
アードバーク・セラピューティクス・インコーポレイテッド |
苦味受容体アゴニストおよび腸シグナル伝達化合物の組み合わせ
|
GB202109087D0
(en)
|
2021-06-24 |
2021-08-11 |
Norwegian Univ Sci & Tech Ntnu |
Therapeutic methods and devices
|